Douglas Giordano

Douglas Ernest Giordano is President & Director at FoldRx Pharmaceuticals LLC.
Holds director roles at ViiV Healthcare Ltd. since 2012, Cerevel Therapeutics LLC, and Cerevel Therapeutics, Inc. Managing Director & Perceptive Discovery Co-Head at Perceptive Advisors (Private Equity) since 2021.
Independent Director at Panacea Acquisition Corp.
II since 2021 and Independent Non-Executive Director at Kardigan, Inc. since 2024.
Member of the Visitors Board at Duke University School of Medicine and Advisor at New Rhein Healthcare Investors.
Former positions include President, Chief Executive Officer & Director at Anacor Pharmaceuticals LLC; Director at ICU Medical, Inc. from 2017 to 2019; Director at KP Pharmaceuticals LLC; Director at Zoetis, Inc. from 2012 to 2013; President, Treasurer & Director at Medivation LLC (California); Director at Viatris, Inc.; President, Treasurer & Director at Array BioPharma, Inc.; Independent Director at Cerevel Therapeutics Holdings, Inc. from 2018 to 2024; Senior VP-Worldwide Business Development at Pfizer Inc. from 2007 to 2021; President at Serenex, Inc.; Vice President at Icagen, Inc.; and President at Encysive Pharmaceuticals, Inc.Education includes undergraduate studies at Duke University and an MBA from Johnson Graduate School of Management.